Drug profile · INN
zongertinib
HERNEXEOS
zongertinib (HERNEXEOS) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Drug details — zongertinib
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 6
- Data quality
- 0.84
Quick answer
zongertinib (HERNEXEOS) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
China Approves HERNEXEOS for Lung Cancer Treatment
Boehringer Ingelheim's HERNEXEOS has received approval in China as an initial treatment for lung cancer, marking a pivotal moment in oncology. This development has far-reaching implications for the pharmaceutical industry.
FDA Accelerated Approvals Oncology: 2026 Policy Review & Zongertinib Case
This article delves into the FDA's 2026 policy review on accelerated approvals in oncology, focusing on the case of Zongertinib for lung cancer therapy.
FDA Accelerated Approval Oncology 2026: Market Analysis & Future Trends
This article delves into the FDA's Accelerated Approval pathway for oncology drugs in 2026, highlighting market dynamics and future trends in cancer treatment.
FDA Accelerated Approvals 2026: Zongertinib and Oncology Policy Shifts
This article delves into the FDA's 2026 accelerated approvals, focusing on Zongertinib's role in oncology and the evolving landscape of cancer treatment policies.
Pipeline programs
Frequently asked questions
What is zongertinib?
zongertinib (HERNEXEOS) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for zongertinib?
HERNEXEOS is a marketed brand name for zongertinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of zongertinib?
zongertinib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.